Chemotherapy for malignant pleural mesothelioma

Linda L. Garland

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Opinion statement: All MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.

Original languageEnglish (US)
Pages (from-to)181-188
Number of pages8
JournalCurrent Treatment Options in Oncology
Issue number2
StatePublished - Jun 2011
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Chemotherapy for malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this